Celsis Outlines the Top Five Advantages of Cryo-plateable H...( Harness the Dual Benefits of...)

Harness the Dual Benefits of Freshly Isolated Plateability and the Efficiencies of Cryopreservation

CHICAGO, June 16 /PRNewswire/ -- In today's competitive environment and economic climate, the financial implications of being the first to file a promising new drug compound or chemical entity cannot be underestimated. Researchers and drug manufacturers are under even greater pressure to do more with less, and productivity and cost savings are at a premium. In the race to succeed, fresh hepatocytes (cells that mimic the properties of the liver and are used by researchers to evaluate the metabolism, drug-drug interaction and toxicity of drug candidates in a cost-effective manner) present a number of challenges.

Celsis International plc (LSE: CEL.L) - a leading global provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical and consumer products industries - outlines several key advantages of using cryopreserved plateable hepatocytes over fresh tissue for drug research.

1. Fewer Restrictions. The limitations of freshly isolated hepatocytes for studies like induction severely restrict the researcher's choices for timing, demographics and retesting. Cryopreservation of these cells permits expanded investigation while retaining clinically significant activity. By removing constraints associated with tissue availability, cryopreservation allows for further testing of activity and genomic characterizations, re-testing from the same donor and scheduling at the researcher's discretion.
2. Best of Both Worlds. Some cryopreserved hepatocyte preparations retain the fresh hepatocytes' ability to attach to a collagen I coated matrix (cryo-plateable), extending their use for long-term culturing applications like induction. Both human and animal cryopreserved hepatocytes offer other benefits as wel
   '/>"/>